iLite® CD3 effector cell/ T-Cell activation Bioassays
The iLite® CD3 Effector Cell line is a reporter gene cell line that offers a convenient and powerful way of measuring the efficacy antibodies have to elicit T cell activation through CD3 interactions.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
In recent years, a variety of immunotherapy strategies aimed at inducing, strengthening, and/or engineering T cell responses have emerged as promising approaches for the treatment of diseases such as cancer and autoimmunity. With the iLite CD3 Effector cell - a cleverly engineered effector cell that closely resembles the natural engagement of the TCR/CD3 complex, and homologous target cells with a controlled antigen expression (+) or depletion (-), this can be assessed with a robust assay. The iLite T-Cell Activation Bioassays is a dual cell system based on bioluminescent cell-based assays. The portfolio consists of cell lines provided in an “assay-ready” format for a rapid and convenient workflow and a further reduction in assay variability and can be used for the discovery and development of novel biologics such as bispecific antibodies and CAR-T cell therapies.
Bispecific antibodies and the quantification of their activity using iLite bioassays
In this application note, the use of therapeutic monoclonal antibodies (mAbs) is discussed as treatment for many disorders. The note also outlines how bispecific antibodies (BsAbs) work, how they are useful, and how cell-based reporter-gene assays can be used as valuable tools in the development of new therapeutic BsAbs. Different configurations and functions of BsAbs are also described, including how they work in the lysis of cancer cells.
Cell-based assays in immuno-oncology: Advancing bispecific antibody development
Explore the importance of robust and reliable cell-based assays in the development of therapeutic bispecific antibodies in immuno-oncology
